Symbol
| CCL21
| contributors: mct/npt - updated : 11-02-2017
|
HGNC name
| chemokine (C-C motif) ligand 21
|
HGNC id
| 10620
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --over
|  
|
in hepatitis C, to modulating lymphocyte recruitment and fibrosis | constitutional
|  
|  
| --over
|  
|
specifically in hyperplastic Myasthenia gravis thymuses | tumoral
|  
|  
| --low
|  
|
in colorectal adenocarcinomas | |
Susceptibility
|
to inflammatory polyarthritis (IP) |
Variant & Polymorphism
other
| CCL21 risk alleles was associated with premature mortality in IP |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
miscelleaneous | urinary | chronic kidney disease | |
CCL21/CCR7 signaling of fibrocytes may provide therapeutic targets for combating renal fibrosis | miscelleaneous | pain | | |
target to a preventive therapy in neuropathic pain |
| | | |
| mice deficient for CCL21 did not develop any signs of tactile allodynia and failed to up-regulate microglial P2X4 receptor expression |